In this video, Motley Fool health care analyst David Williamson gives us the story behind two big biotech jumps today and two big stumbles. Sequenom (NASDAQ: SQNM) continues its rally from Friday with more good news that its RetnaGene AMD accurately predicts the progression of wet age-related macular degeneration; this has shares up an additional 8% on top of Friday's 19%. Repros Therapeutics (NASDAQ: RPRX) also up today ahead of presenting both of its phase 2 drugs, Androxal and Proellex, at the Lazard conference tomorrow. Meanwhile, Cyclacel (NASDAQ: CYCC) and Transcept (NASDAQ: TSPT) are both down today after disappointing earnings releases.
Nov 13, 2012 at 2:55PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 05/10/2021.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return